サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1513947

過活動膀胱（OAB）治療薬の世界市場

Overactive Bladder (OAB) Therapeutics

出版日
ページ情報
英文 271 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
過活動膀胱（OAB）治療薬の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 271 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

過活動膀胱（OAB）治療薬の世界市場は2030年までに15億米ドルに達する見込み

2023年に12億米ドルと推定される過活動膀胱（OAB）治療薬の世界市場は、2030年には15億米ドルに達し、分析期間2023-2030年のCAGRは2.8%で成長すると予測されます。本レポートで分析したセグメントの1つである抗コリン薬は、CAGR 3.1%を記録し、分析期間終了時には6億1,470万米ドルに達すると予測されます。神経刺激療法分野の成長率は、分析期間中CAGR 2.4%と推定されます。

米国市場は推定3億3,230万米ドル、中国はCAGR4.8％で成長予測

米国の過活動膀胱（OAB）治療薬市場は、2023年に3億3,230万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 4.8%で推移し、2030年には2億9,070万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.5%と2.3%と予測されています。欧州では、ドイツがCAGR 1.9%で成長すると予測されています。

過活動膀胱（OAB）治療薬-主要動向と促進要因

過活動膀胱（OAB）は、膀胱壁の筋肉の突然の不随意収縮を特徴とする泌尿器科疾患で、緊急の尿意につながります。この疾患は世界中で数百万人が罹患しており、高齢者と女性の罹患率が高いです。OABは生活の質に大きな影響を与え、社会的、心理的、身体的苦痛を引き起こします。OABの治療には、抗ムスカリン薬、β3アドレナリン作動薬、ボツリヌス毒素注射のような新しい治療法など、さまざまな薬物療法があります。これらの治療は、膀胱の筋肉を弛緩させ、頻尿を減らし、症状を効果的に管理することを目的としています。OAB治療薬の市場は進化しており、より有効性が高く、副作用が少なく、患者のコンプライアンスを改善する薬剤の開発に焦点を当てた研究が進められています。

いくつかの動向がOAB治療薬の状況を形成しています。重要な動向の1つは個別化医療へのシフトであり、治療法を個人の遺伝的プロファイルや特定の症状に合わせて調整することで、治療成績が向上します。経皮パッチや徐放性製剤などのドラッグデリバリーシステムの革新は、投与回数を減らし副作用を最小限に抑えることで、患者のアドヒアランスを向上させています。さらに、膀胱のコントロールに関与する複数の経路をターゲットとする併用療法の開発が盛んになっており、より包括的な症状管理を提供しています。モバイルヘルスアプリケーションやウェアラブルデバイスを含むデジタルヘルス技術は、OAB管理にますます統合されつつあり、リアルタイムの症状追跡や個別化された治療調整を可能にしています。さらに、薬物治療に反応しない患者に代替治療の選択肢を提供する神経調節技術などの非薬物学的介入への関心も高まっています。

OAB治療薬市場の成長は、いくつかの要因によってもたらされます。薬物製剤やドラッグデリバリーシステムの技術的進歩により、治療がより効果的で使い勝手の良いものとなり、需要を牽引しています。OABに罹患しやすい世界人口の高齢化が、対処可能な市場を大幅に拡大しています。教育キャンペーンや診断ツールの改善に後押しされたOABの認知度や診断率の向上が、治療普及率の上昇につながっています。さらに、OABの危険因子である糖尿病や肥満などの生活習慣病の有病率の上昇が市場成長に寄与しています。製薬企業は、優れた有効性と安全性を備えた新規治療薬を導入するため、研究開発に多額の投資を行っています。デジタルヘルスソリューションの統合により、患者のエンゲージメントと治療レジメンへのアドヒアランスが向上しています。さらに、特に新興市場における有利な償還政策とヘルスケア・インフラの整備が、市場の拡大を後押ししています。これらの要因が複合的に作用することで、OAB治療薬市場の堅調な成長が促進され、罹患者のより良い管理と生活の質の向上が保証されます。

調査対象企業の例（全34件）

  • Allergan PLC
  • Astellas Pharma, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo Pharmaceuticals, Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Recordati SpA
  • Speciality European Pharma Ltd.
  • Sunovion Pharmaceuticals, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6499

Global Overactive Bladder (OAB) Therapeutics Market to Reach US$1.5 Billion by 2030

The global market for Overactive Bladder (OAB) Therapeutics estimated at US$1.2 Billion in the year 2023, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2023-2030. Anticholinergics Therapy, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$614.7 Million by the end of the analysis period. Growth in the Neurostimulation Therapy segment is estimated at 2.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$332.3 Million While China is Forecast to Grow at 4.8% CAGR

The Overactive Bladder (OAB) Therapeutics market in the U.S. is estimated at US$332.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$290.7 Million by the year 2030 trailing a CAGR of 4.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Overactive Bladder (OAB) Therapeutics - Key Trends and Drivers

Overactive Bladder (OAB) is a prevalent urological condition characterized by a sudden, involuntary contraction of the muscle in the wall of the urinary bladder, leading to an urgent need to urinate. This condition affects millions of people worldwide, with a higher incidence among the elderly and women. OAB significantly impacts the quality of life, causing social, psychological, and physical distress. Therapeutics for OAB include a range of pharmacological treatments such as antimuscarinics, beta-3 adrenergic agonists, and newer modalities like botulinum toxin injections. These treatments aim to relax the bladder muscle, reduce urinary frequency, and manage symptoms effectively. The market for OAB therapeutics is evolving, with ongoing research focused on developing drugs with better efficacy, fewer side effects, and improved patient compliance.

Several trends are shaping the landscape of OAB therapeutics. One significant trend is the shift towards personalized medicine, where treatments are tailored to the individual’s genetic profile and specific symptoms, thereby enhancing treatment outcomes. Innovations in drug delivery systems, such as transdermal patches and extended-release formulations, are improving patient adherence by reducing the frequency of dosing and minimizing side effects. Additionally, the development of combination therapies that target multiple pathways involved in bladder control is gaining traction, offering more comprehensive symptom management. Digital health technologies, including mobile health applications and wearable devices, are increasingly being integrated into OAB management, enabling real-time symptom tracking and personalized treatment adjustments. Furthermore, there is growing interest in non-pharmacological interventions, such as neuromodulation techniques, which offer alternative treatment options for patients who do not respond well to medication.

The growth in the OAB therapeutics market is driven by several factors. Technological advancements in drug formulation and delivery systems are making treatments more effective and user-friendly, thereby driving demand. The aging global population, which is more susceptible to OAB, is significantly expanding the addressable market. Increased awareness and diagnosis rates of OAB, fueled by educational campaigns and improved diagnostic tools, are leading to higher treatment adoption. Additionally, the rising prevalence of lifestyle diseases such as diabetes and obesity, which are risk factors for OAB, is contributing to market growth. Pharmaceutical companies are investing heavily in research and development to introduce novel therapeutics with superior efficacy and safety profiles. The integration of digital health solutions is enhancing patient engagement and adherence to treatment regimens. Furthermore, favorable reimbursement policies and healthcare infrastructure improvements, particularly in emerging markets, are supporting market expansion. The collective impact of these factors is fostering robust growth in the OAB therapeutics market, ensuring better management and improved quality of life for affected individuals.

Select Competitors (Total 34 Featured) -

  • Allergan PLC
  • Astellas Pharma, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo Pharmaceuticals, Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Recordati SpA
  • Speciality European Pharma Ltd.
  • Sunovion Pharmaceuticals, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Overactive Bladder (OAB) Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Aging Global Population Expands Addressable Market Opportunity for OAB Therapeutics
    • Innovations in Drug Delivery Systems Propel Growth in OAB Treatment Solutions
    • Personalized Medicine Throws the Spotlight on Tailored OAB Therapeutic Approaches
    • Advances in Neuromodulation Techniques Strengthen Business Case for Non-Pharmacological Interventions
    • Increased Awareness and Diagnosis Rates Drive Adoption of OAB Treatments
    • Rising Prevalence of Lifestyle Diseases Generates Demand for OAB Therapeutics
    • Integration of Digital Health Technologies Accelerates Demand for Real-Time Symptom Management
    • Development of Combination Therapies Enhance Comprehensive Symptom Control
    • Improved Diagnostic Tools Enhanced Early Detection and Treatment
    • Technological Advancements in Extended-Release Formulations Sustain Growth in OAB Market
    • Consumer Preference for Non-Invasive Treatments Expands Market for Alternative Therapies
    • Economic Burden of Untreated OAB Fuels Demand for Effective Management Solutions
    • Impact of Telemedicine Services on Enhancing Patient Access and Treatment Compliance
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Overactive Bladder (OAB) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Anticholinergics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Neurostimulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Neurostimulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Neurostimulation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Botox by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Botox by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Botox by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Mirabegron by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Mirabegron by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Mirabegron by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • JAPAN
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • CHINA
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • EUROPE
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • FRANCE
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • GERMANY
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Spain 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Russia 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Australia 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • INDIA
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: India Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: India 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: South Korea 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Argentina 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Brazil 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Mexico 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Latin America 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Overactive Bladder (OAB) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Iran 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Israel 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Saudi Arabia 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: UAE 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Middle East 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030
  • AFRICA
    • Overactive Bladder (OAB) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Anticholinergics, Neurostimulation, Botox and Mirabegron Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Africa 16-Year Perspective for Overactive Bladder (OAB) Therapeutics by Pharmacotherapy - Percentage Breakdown of Value Sales for Anticholinergics, Neurostimulation, Botox and Mirabegron for the Years 2014, 2024 & 2030

IV. COMPETITION